vaccin
biolog
prepar
augment
immun
target
diseas
biolog
prepar
stimul
recipi
immun
system
recogn
target
aspect
infecti
organ
foreign
gener
host
mechan
control
elimin
addit
evok
mechan
form
immunolog
memori
antigen
provid
efficaci
futur
infect
similar
organ
vaccin
creat
inactiv
attenu
organ
deriv
purifi
recombin
subcompon
organ
provid
antigen
may
incorpor
vaccin
compos
peptid
protein
polysaccharid
may
also
indirectli
introduc
host
immun
system
recombin
dna
plasmid
chimer
viru
vector
inactiv
vaccin
kill
use
heat
chemic
wherea
attenu
vaccin
contain
live
less
virul
organ
often
vaccin
deriv
live
virus
cultur
condit
disabl
pathogen
properti
attenu
vaccin
often
produc
durabl
immunolog
respons
thu
prefer
mani
class
infecti
agent
subcompon
microorgan
may
also
use
antigen
vaccin
exampl
toxoid
vaccin
made
inactiv
toxic
compon
offer
protect
effect
infect
addit
fragment
subunit
attenu
inactiv
microorgan
also
use
basi
antigen
respons
vaccin
subcompon
may
also
use
purpos
exampl
poorli
immunogen
compon
microorgan
improv
conjug
protein
typic
toxin
approach
often
use
conjunct
polysaccharid
form
outer
coat
infecti
bacteria
haemophilu
influenza
type
b
vaccin
immun
dna
plasmid
viru
vector
involv
vaccin
encod
antigen
protein
subsequ
express
within
cell
recipi
follow
administr
vaccin
monoval
vaccin
design
provok
immun
respons
singl
antigen
microorgan
multival
polyval
vaccin
meant
evok
immun
respons
sever
antigen
microorgan
howev
variou
antigen
combin
synergist
inhibitori
interact
potenti
outcom
term
immunolog
respons
process
vaccin
introduc
extern
substanc
host
immun
system
induc
increas
respons
specif
antigen
suffici
vigor
provid
level
immun
prevent
onset
diseas
protect
host
futur
risk
infecti
diseas
respons
vaccin
follow
complex
coordin
set
physiolog
immunebas
reaction
tightli
control
involv
differ
cell
type
biochem
intermedi
antibodi
cellmedi
respons
may
occur
follow
immun
variou
vaccin
antigen
significantli
influenc
type
adjuv
use
vaccin
product
host
respons
antigen
within
vaccin
encompass
adapt
humor
cellmedi
immun
respons
innat
immun
respons
antigenpres
cell
apc
bcell
tcell
initi
involv
vaccin
protein
peptid
present
apc
interact
directli
tcell
receptor
recogn
specif
amino
acid
sequenc
associ
class
class
ii
mhc
receptor
humor
antibodi
product
mediat
bcell
humor
respons
includ
neutral
nonneutr
antibodi
involv
complementdepend
independ
mechan
may
involv
tcell
depend
interact
helper
tcell
depend
lytic
solubl
factor
activ
vaccineinduc
effector
immun
typic
antibodi
produc
blymphocyt
potenti
effector
immun
cytotox
lymphocyt
ctl
also
involv
activ
effector
mediat
regulatori
tcell
treg
maintain
immun
toler
repres
peripher
tcell
popul
cell
serv
inhibit
immun
respons
potenti
harm
inhibit
increas
activ
treg
activ
believ
play
role
control
autoimmun
diseas
could
possibl
aris
wayward
respons
antigen
contain
vaccin
antigen
spread
respons
interact
vaccin
antigen
adjuv
treg
like
remain
unclear
requir
research
gener
mainten
band
tcell
govern
activ
helper
lymphocyt
cell
frequent
subdivid
helper
helper
subtyp
antigen
recogn
antibodi
tcell
receptor
howev
antigen
evok
suffici
immun
respons
make
suitabl
vaccin
compon
overcom
limit
weak
antigen
variou
chang
sometim
made
vaccin
may
take
form
conjug
antigen
andor
enhanc
immun
respons
inclus
addit
vaccin
compon
adjuv
exampl
abil
elicit
immun
respons
antigen
compon
streptococcu
pneumonia
heptaval
triskaival
vaccin
increas
conjug
protein
diphtheria
protein
addit
respons
variou
antigen
affect
variou
factor
dose
concentr
antigen
quantiti
natur
adjuv
time
inocul
rout
exposur
follow
inocul
vaccin
primari
secondari
immun
respons
occur
schedul
inject
vaccin
import
determin
immun
respons
may
vari
among
differ
vaccin
initi
primari
exposur
immun
respons
subsequ
secondari
exposur
mediat
specif
popul
cell
name
short
longliv
antibodi
secret
plasma
cell
memori
bcell
preclin
toxicolog
vaccin
evok
effect
immun
respons
vaccin
varieti
adjuv
chemic
biolog
addit
may
use
tabl
edelman
griffin
use
classifi
adjuv
two
group
substanc
increas
immun
respons
antigen
immunogen
protein
modifi
tcell
activ
enhanc
uptak
antigenpres
phagocyt
cell
protein
antigen
denatur
precipit
alum
adjuv
antigen
depot
creat
exampl
oilbas
adjuv
slow
releas
antigen
occur
period
week
evok
strong
immun
reaction
bcell
stimul
may
also
produc
enhanc
antibodi
respons
may
achiev
use
deae
dextran
bacteri
toxin
adjuv
may
target
innat
respons
necessari
activ
specif
pathway
acquir
immun
increas
activ
cell
result
enhanc
cellmedi
immun
cmi
select
activ
innat
immun
mediat
tolllik
cell
surfac
receptor
could
caus
microbi
cpg
adjuv
aluminumbas
adjuv
well
establish
wide
use
although
basi
action
remain
unclear
postul
aluminumbas
vaccin
may
function
variou
way
includ
follow
creation
depot
maintain
present
antigen
stimul
antigen
present
cell
apc
format
particul
antigen
otherwis
solubl
antigen
increas
immunolog
respons
pharmacolog
effect
mediat
inflammasom
spite
fact
alumbas
vaccin
gener
well
toler
adjuv
may
produc
granuloma
subcutan
intraderm
inject
advers
effect
associ
intramuscular
rout
inject
number
vaccin
current
use
contain
aluminum
adjuv
although
less
adjuv
activ
recent
develop
adjuv
extens
human
experi
make
use
frequent
choic
vaccin
candid
commonli
use
aluminum
adjuv
avail
varieti
form
aluminum
phosphat
alpo
aluminum
hydroxid
al
oh
potassium
aluminum
sulfat
kal
term
alum
specif
refer
potassium
aluminum
sulfat
although
may
use
broader
context
refer
aluminum
salt
element
aluminum
content
licens
us
vaccin
limit
mg
per
individu
dose
vaccin
aluminum
salt
may
remain
site
inject
long
period
time
portion
aluminum
salt
intern
dendrit
cell
nevertheless
undergo
biodistribut
excret
extend
period
time
despit
aluminum
salt
extens
record
experi
safeti
ideal
adjuv
signific
problem
potenti
lack
consist
adsorpt
antigen
differ
lot
brand
type
aluminum
salt
demonstr
inconsist
adsorpt
capac
furthermor
potenti
exist
exchang
protein
antigen
adsorb
aluminum
salt
interstiti
protein
inject
variat
adsorpt
capac
situ
interact
like
due
number
chemic
forc
bind
antigen
aluminum
adjuv
bind
involv
varieti
factor
includ
electrostat
bond
hydrophob
interact
van
der
waal
forc
hydrogen
bond
strength
depend
charg
aluminum
salt
protein
antigen
physic
structur
aluminum
salt
ph
buffer
use
typic
aluminum
salt
induc
local
red
swell
inject
site
toxic
readili
toler
local
inflamm
intramuscular
inject
aluminum
salt
thought
occur
materi
migrat
subcutan
space
follow
needl
track
creat
upon
inject
vaccin
addit
nodul
may
occur
repeat
inject
adjuv
associ
subcutan
rout
inject
howev
advers
clinic
find
regard
aluminum
contain
adjuv
al
oh
produc
macrophag
myofasi
mmf
begin
increas
number
case
report
unusu
infiltr
skelet
muscl
connect
tissu
structur
nonepithelioid
histiocyt
cell
patient
tend
exhibit
chronic
myalgia
affect
limb
cluster
find
present
coher
pictur
associ
mmf
aluminum
salt
case
exhibit
common
characterist
site
macrophag
infiltr
focal
typic
restrict
site
inject
muscl
damag
almost
alway
absent
infiltr
macrophag
form
well
delin
sheet
histocyt
find
led
conclus
mmf
result
longterm
persist
aluminum
hydroxid
site
inject
vaccin
underli
caus
human
toxic
remain
unclear
may
relat
impair
elimin
aluminum
genet
disposit
inflammatori
diseas
respect
latter
authier
et
al
examin
whether
differ
bias
immun
could
influenc
express
mmf
rodent
anim
model
author
found
lewi
rat
immun
respons
differ
reaction
aluminum
hydroxid
adjuv
vaccin
spraguedawley
rat
balanc
immun
respons
lewi
rat
demonstr
significantli
smaller
mmf
lesion
spraguedawley
rat
anoth
studi
monkey
given
diphtheriatetanu
vaccin
contain
aluminium
adjuv
found
vari
degre
macrophag
aggreg
site
inject
although
evid
either
behavior
muscular
weak
evid
meet
issu
mmf
highlight
need
research
topic
newer
recombin
synthet
antigen
vaccin
gener
less
immunogen
older
live
kill
attenu
whole
organismbas
vaccin
result
develop
power
adjuv
compens
potenti
diminish
immun
respons
nevertheless
alum
remain
major
adjuv
use
vaccin
use
immun
human
alum
propens
induc
effect
level
antibodi
mediat
respons
littl
capac
stimul
cellular
respons
mediat
mechan
latter
import
aspect
immun
newer
effort
develop
vaccin
addit
novel
adjuv
address
need
develop
power
antibodi
respons
human
popul
insuffici
respons
vaccin
use
alum
newborn
elderli
immunocompromis
individu
also
reduc
amount
administ
antigen
antigen
spare
although
number
recent
develop
adjuv
clearli
demonstr
potenti
increas
immunogen
concern
safeti
remain
adjuv
may
classifi
variou
way
reflect
variou
properti
see
tabl
vaccin
typic
produc
variou
advers
clinic
effect
inflamm
pain
site
inject
malais
fatigu
slight
febril
respons
may
counterpart
express
toxic
studi
infiltr
inflammatori
cell
site
administr
decreas
food
consumpt
loss
bodi
weight
elev
bodi
temperatur
advers
effect
reflect
activ
variou
compon
immun
system
vari
specif
natur
vaccin
antigen
andor
adjuv
similarli
natur
occur
infect
administr
vaccin
result
activ
cell
regul
immun
result
inflamm
accompani
releas
variou
proinflammatori
cytokin
frequent
evok
acut
phase
respons
exampl
van
der
beek
et
al
report
administr
attenu
yellow
fever
vaccin
healthi
human
subject
crp
fibrinogen
found
elev
blood
sampl
similar
studi
reveal
increas
blood
level
variou
cytokin
acut
phase
reactant
involv
immun
inflammatori
respons
reinhardt
et
al
observ
increas
administr
yellow
fever
vaccin
addit
hacker
et
al
found
increas
plasma
level
tnf
adminstr
vaccin
express
inflammatori
cytokin
entri
bloodstream
contribut
express
system
manifest
toxic
like
fever
malais
sometim
observ
administr
vaccin
clinic
popul
adddit
physiolog
effect
well
character
requir
investig
determin
impact
overal
safeti
exampl
liuba
et
al
report
decreas
flowmedi
dilat
respons
indic
alter
arteri
endotheli
function
measur
brachial
arteri
human
subject
persist
week
follow
administr
inactiv
trival
split
influenza
vaccin
chang
arteri
respons
hyperemia
accompani
small
increas
crp
fibrinogen
level
consid
small
number
human
subject
found
administr
attenu
capsular
polysaccharid
vaccin
salmonella
typhi
signific
dysregul
arteri
endotheli
function
occur
resist
conduit
blood
vessel
accompani
system
inflammatori
respons
character
elev
white
blood
cell
count
serum
level
receptor
antagonist
beyond
influenc
cardiovascular
physiolog
chang
underli
cytokin
level
report
factor
alter
neg
mood
affect
follow
administr
typhi
vaccin
may
link
direct
influenc
inflammatori
action
vaccin
malais
lethargi
impair
cognit
abil
sometim
observ
clinic
popul
rare
seriou
advers
event
associ
administr
vaccin
mani
instanc
possibl
demonstr
definit
link
vaccin
seriou
signific
toxic
given
small
amount
materi
administ
vaccin
direct
local
system
toxic
extrem
rare
commonli
toxic
associ
vaccin
aris
variou
factor
involv
inflammatori
event
intrins
part
respons
administ
antigen
andor
adjuv
addit
vaccin
may
contain
excipi
preserv
includ
antibiot
may
link
toxic
addit
compon
serv
variou
purpos
exampl
chemic
ad
product
prevent
bacteri
growth
remain
manufactur
process
extran
protein
like
egg
protein
influenza
vaccin
formalin
found
trace
amount
sever
vaccin
product
vaccin
frequent
given
intramuscular
inject
addit
toxic
caus
vaccin
compon
trauma
caus
inject
introduc
histolog
chang
site
inject
must
consid
rel
pictur
inflamm
caus
vaccin
thuillez
et
al
summar
find
studi
conduct
use
rat
mice
rabbit
singl
repeat
inject
salin
mice
inject
right
left
gluteu
medium
muscl
rat
left
right
gluteu
medium
left
right
quadricep
femori
muscl
rabbit
dorsolumbar
muscl
mice
given
ml
wherea
rat
given
ml
rabbit
ml
author
report
day
intramuscular
inject
lesion
consist
mainli
infiltr
inflammatori
cell
consist
neutrophil
heterophil
lymphocyt
macrophag
hemorrhag
myofib
degener
andor
muscl
necrosi
day
follow
inject
site
contain
reduc
number
inflammatori
cell
along
histolog
evid
heal
includ
regener
myofib
fibrosi
find
consist
local
minim
trauma
intramuscular
inject
vaccin
includ
alum
show
similar
histolog
pictur
verdier
et
al
investig
local
histolog
effect
two
aluminumcontain
vaccin
monkey
singl
intramuscular
inject
month
investig
two
group
monkey
immun
either
diptheriatetanu
vaccin
adjuv
aluminum
hydroxid
aluminum
phosphat
month
aggreg
macrophag
accompani
lymphocyt
infiltr
found
site
inject
one
monkey
given
aluminum
hydroxid
found
cystlik
structur
line
macrophag
fibrocyt
later
histolog
examin
reveal
minim
number
lymphocyt
without
focal
fibrosi
anim
given
aluminum
phosphat
greatli
diminish
year
monkey
given
vaccin
contain
aluminum
hydroxid
aggreg
macrophag
evid
anim
remain
year
addit
isol
exampl
toxic
enhanc
diseas
associ
vaccin
known
suspect
aspect
case
appear
mimic
cours
increas
diseas
sever
advers
event
due
natur
infect
wellestablish
exampl
increas
diseas
sever
occur
respiratori
syncyti
dengu
measl
viru
infect
children
immun
formalininactiv
respiratori
syncyti
viru
fi
rsv
rsv
g
vaccin
infect
rsv
infect
associ
enhanc
diseas
pulmonari
eosinophilia
believ
due
exagger
memori
respons
anim
model
respiratori
syncyt
viru
infect
suggest
variou
mechan
causal
role
includ
sensit
antibodi
untoward
site
unfavor
tcell
respons
overexuber
immun
respons
involv
cytokin
interleukin
anoth
seriou
potenti
toxic
infrequ
associ
vaccin
autoimmun
diseas
regard
three
differ
mechan
may
work
name
molecular
mimicri
epitop
spread
autoimmun
dysregul
incid
autoimmuneinduc
diseas
low
mani
case
reliabl
associ
administr
vaccin
although
unequivoc
associ
known
variou
possibl
pathogen
mechan
exist
molecular
mimicri
result
immun
respons
share
epitop
antigen
host
antigen
compon
vaccin
access
potenti
toxic
protein
sequenc
may
screen
comput
base
search
amino
acid
structur
antigen
protein
compon
known
protein
structur
anoth
possibl
mechan
autoimmun
phenomenon
epitop
spread
three
differ
type
believ
possibl
share
ident
amino
acid
sequenc
peptid
andor
protein
homolog
nonident
amino
acid
sequenc
epitop
dissimilar
chemic
structur
dna
peptid
carbohydr
peptid
although
immun
respons
unintend
antigen
may
indirect
lower
affin
avid
could
theoret
suffici
strength
provok
antibodymedi
cytotox
activ
complement
cellmedi
signal
molecular
mimicri
tcell
differ
mediat
antibodi
mimicri
tcell
type
immun
degeneraci
tcell
recogn
respond
untoward
antigen
tcell
may
exhibit
epitop
spread
respons
direct
origin
epitop
recognit
epitop
target
tissu
protein
express
inflammatori
process
caus
vaccin
addit
theoret
mechan
exist
includ
activ
superantigen
larg
fraction
tcell
popul
induct
inflammatori
cytokin
costimulatori
molecul
current
howev
lack
vivo
evid
molecular
mimicri
associ
vaccin
although
remain
issu
concern
toxicolog
studi
vaccin
adjuv
fda
regul
preclin
toxicolog
studi
vaccin
requir
compon
eg
antigen
adjuv
also
test
advers
effect
studi
follow
good
laboratori
practic
glp
guidelin
describ
code
feder
regul
cfr
gener
five
type
toxicolog
studi
singl
andor
repeat
dose
reproduct
development
mutagen
carcinogen
safeti
pharmacolog
normal
includ
repeatdos
toxic
studi
need
develop
new
vaccin
requir
preclin
test
advers
effect
local
system
test
articl
depend
stage
vaccin
develop
singl
andor
multipl
dose
dose
respons
andor
time
respons
studi
conduct
speci
select
studi
base
desir
clinic
immun
respons
exampl
mice
use
replic
cellular
immun
respons
altern
anim
model
rabbit
use
reproduc
humor
immun
respons
select
criteria
anatom
physiolog
relev
human
may
consid
studi
intracutan
topic
vaccin
minipig
consid
good
model
baboon
use
investig
novel
adjuv
intranas
immun
physiolog
pharmacolog
similar
human
specif
investig
rsv
vaccin
hamster
sometim
use
anim
model
vaccin
preclin
toxicolog
studi
discuss
detail
later
chapter
differ
vaccin
andor
adjuv
may
requir
differ
approach
immunogen
test
enhanc
iga
respons
might
appropri
mucos
vaccin
develop
tcellmedi
respons
may
play
key
role
vaccin
immunogen
import
humor
respons
see
introduct
section
preclin
toxicolog
studi
care
design
includ
relev
speci
also
appropri
number
anim
eg
rabbit
micesexgroup
main
recoveri
group
rout
administr
test
articl
normal
intend
clinic
rout
dose
level
intend
clinic
dose
number
dose
n
n
number
clinic
dose
number
dose
n
number
employ
justifi
number
anim
group
glp
system
mean
organiz
structur
respons
procedur
process
resourc
implement
qualiti
manag
conduct
nonclin
laboratori
studi
part
regul
includ
specif
glp
requir
vivo
vitro
studi
part
cfr
explain
glp
requir
handl
toxicolog
studi
record
requir
diagnost
product
human
use
respect
adequ
ensur
reliabl
statist
analysi
data
perform
suffici
statist
power
evalu
potenti
differ
studi
design
includ
treatment
group
includ
test
vehicl
adjuv
antigen
stabil
test
control
articl
determin
studi
initi
concomitantli
accord
approv
standard
oper
procedur
sop
provid
period
analysi
batch
stabil
test
articl
ensur
deliveri
consist
concentr
activ
materi
turn
ensur
consist
immun
respons
nonclinicalclin
studi
preclin
studi
protocol
written
follow
instruct
cfr
part
preclin
laboratori
studi
conduct
accord
protocol
protocol
amend
deviat
includ
final
report
detail
report
nonclin
laboratori
studi
result
includ
cfr
part
toxicolog
studi
includ
packag
investig
new
drug
ind
applic
toxicolog
studi
normal
includ
follow
endpoint
cagesid
clinic
observ
mortal
morbid
gener
health
sign
toxic
monitor
daili
basi
evalu
skin
fur
eye
mucu
membran
respiratori
circulatori
autonom
central
nervou
system
somatomotor
behavior
record
daili
basi
weekli
time
minim
mild
chang
anim
health
due
vaccin
treatment
chang
anim
health
due
test
articl
treatment
could
seriou
requir
immedi
attent
rare
case
requir
termin
anim
includ
recoveri
group
studi
help
determin
whether
chang
recover
time
food
consumpt
bodi
weight
chang
food
consumpt
bodi
weight
could
indic
advers
effect
test
articl
physiolog
event
trigger
respons
ingest
food
import
episod
signal
initi
brain
detect
via
sensori
input
amount
food
ingest
nutrient
content
special
chemoand
mechanoreceptor
monitor
physiolog
activ
locat
gastrointestin
tract
pass
inform
brain
mainli
via
vagu
nerv
affer
inform
constitut
one
class
satieti
signal
form
part
preabsorpt
control
appetit
appetit
control
chemic
releas
gastric
stimuli
food
process
gastrointestin
tract
chang
food
consumpt
might
caus
mani
chemic
peptid
neurotransmitt
releas
cholecystokinin
cck
hormon
believ
mediat
meal
termin
trigger
food
consumpt
turn
activ
ccka
receptor
pylor
region
stomach
vagu
nerv
transmit
signal
nucleu
tractu
solitariu
nt
brain
stem
signal
relay
hypothalam
region
integr
signal
occur
peptid
enterostatin
neurotensin
glucagonlikepeptid
repres
potenti
peripher
satieti
signal
advers
effect
test
articl
chemic
affect
appetitefood
consumpt
chang
food
consumpt
turn
affect
bodi
weight
bodi
temperatur
bodi
temperatur
immun
system
close
relat
infect
signal
brain
control
bodi
temperatur
sent
infect
elev
temperatur
entir
bodi
caus
fever
real
infect
exist
vaccin
immun
system
may
perceiv
one
bodi
learn
fight
real
infect
vaccin
bodi
temperatur
measur
hour
dose
inject
site
evalu
draiz
score
could
use
inject
site
evalu
includ
evalu
edema
erythema
eschar
format
site
inject
evalu
predos
hour
post
dose
inflammatori
skin
reaction
grade
accord
draiz
modifi
scale
ophthalmolog
examin
eye
normal
examin
predos
week
prior
schedul
necropsi
exam
could
includ
observ
intern
extern
structur
eye
cornea
len
transplant
media
aqueou
vitreou
humor
fundu
includ
blood
vascular
optic
disc
ophthalmolog
examin
could
eg
uveiti
indic
inflamm
eye
report
vaccin
clinic
chemistri
blood
sampl
clinic
chemistri
evalu
could
collect
lithium
heparin
tube
plasma
clinic
chemistri
test
use
diagnos
diseas
monitor
diseas
progress
respons
therapi
toxin
exposur
screen
presenc
underli
diseas
appar
healthi
anim
wide
varieti
clinic
chemistri
test
use
purpos
result
follow
paramet
includ
clinic
chemistri
test
electrolyt
balanc
calcium
chlorid
phosphoru
potassium
sodium
chang
free
water
chang
electrolyt
rate
intak
excretionloss
transloc
within
bodi
affect
electrolyt
level
blood
electrolyt
essenti
proper
function
cell
bodi
maintain
electrolyt
concentr
within
narrow
limit
b
carbohydr
metabol
glucos
princip
sourc
energi
mammalian
cell
sourc
glucos
includ
digest
dietari
carbohydr
breakdown
glycogen
liver
glycogenolysi
product
glucos
amino
acid
precursor
liver
gluconeogenesi
hormon
eg
insulin
glucagon
catecholamin
growth
hormon
corticosteroid
affect
blood
glucos
concentr
facilit
entri
remov
circul
chang
blood
glucos
level
due
test
articl
treatment
could
indic
advers
event
abovement
pathway
c
liver
function
alanin
animotransferas
alt
aspart
aminotransferas
ast
sorbitol
dehydrogenas
sdh
glutam
dehydrogenas
gldh
total
bile
acid
alkalin
phosphat
alp
gammaglutamyl
transferas
ggt
total
bilirubin
injuri
liver
parenchym
cell
detect
measur
hepatocellular
leakag
enzym
alt
ast
sdh
gldh
enzym
leakag
cell
damag
cell
membran
indic
increas
serum
activ
enzym
cholestasi
impli
impair
bile
flow
diagnos
chang
alp
ggt
level
cholestasi
result
elev
bilirubin
blood
sever
main
valu
enzym
greater
sensit
abnorm
compar
serum
bilirubin
level
alon
ggt
specif
alkalin
phosphatas
purpos
ck
present
high
concentr
cytoplasm
myocyt
wide
use
enzym
evalu
neuromuscular
diseas
leakag
enzym
enzym
function
make
atp
avail
contract
muscl
done
phosphoryl
adp
creatin
phosphat
catalyz
revers
phosphoryl
creatin
atp
form
phosphocreatin
adp
phosphocreatin
major
storag
form
high
energi
phosphat
muscl
lactat
dehydrogenas
enzym
catalyz
convers
lactat
pyruv
tissuespecif
found
varieti
tissu
includ
liver
heart
skelet
muscl
ldh
level
could
elev
exercis
liver
diseas
muscl
diseas
neoplasia
e
kidney
function
creatin
blood
urea
nitrogen
urea
creatinin
test
normal
use
indic
glomerular
filtrat
rate
gfr
ammonia
gener
catabol
amino
acid
deriv
either
digest
protein
intestin
endogen
tissu
protein
use
hepatocyt
synthes
urea
urea
excret
kidney
intestin
saliva
sweat
urea
middl
layer
eye
call
uvea
provid
blood
suppli
retina
uveiti
swell
irrit
uvea
could
caus
autoimmun
disord
rheumatoid
arthriti
ankylos
spondyl
infect
exposur
toxin
pubm
health
http
nitrogen
concentr
depend
upon
hepat
urea
product
renal
tubular
flow
rate
increas
protein
catabol
digest
decreas
gfr
caus
increas
urea
nitrogen
level
urea
nitrogen
level
decreas
protein
intak
decreas
protein
anabol
increas
excret
decreas
product
eg
liver
diseas
muscl
metabol
result
product
creatinin
energystor
molecul
muscl
call
phosphocreatin
undergo
spontan
cycliz
form
creatin
inorgan
phosphor
creatinin
result
creatin
decomposit
f
protein
total
protein
albumin
globulin
g
ratio
total
protein
albumin
measur
paramet
globulin
g
ratio
calcul
quantit
valu
major
protein
test
result
howev
mani
differ
type
protein
within
globulin
fraction
besid
immun
globulin
associ
acut
phase
respons
measur
provid
inform
fraction
quantit
qualit
data
differ
fraction
compris
total
protein
could
obtain
electrophoresi
electrophoresi
use
serum
urin
bodi
caviti
fluid
sampl
eg
cerebrospin
fluid
g
lipid
triglycerid
cholesterol
serum
triglycerid
incorpor
lipoprotein
compos
coat
phospholipid
cholesterol
protein
apolipoprotein
enclos
hydrophob
center
cholesterol
ester
triglycerid
commonli
occur
steroid
cholesterol
cholesterol
precursor
cholesterol
ester
bile
acid
steroid
hormon
deriv
dietari
sourc
synthes
vivo
acetylcoa
liver
main
site
tissu
intestin
adren
gland
reproduct
organ
hematolog
blood
sampl
hematolog
evalu
could
collect
tube
contain
edta
blood
sampl
fibrinogen
prothrombin
time
activ
partialthromboplastin
time
could
collect
tube
contain
sodium
citrat
follow
paramet
includ
hematolog
test
red
blood
cell
hematocrit
hemoglobin
mean
corp
hb
mean
corp
hb
conc
mean
corp
volum
total
erythrocyt
count
reticulocyt
hematocrit
hct
calcul
product
mean
cell
volum
mcv
red
blood
cell
rbc
count
pack
cell
volum
pcv
directli
measur
valu
obtain
centrifug
blood
microhematocrit
tube
microhematocrit
centrifug
hemoglobin
concentr
hb
report
gram
hemoglobin
per
decilit
blood
gdl
hemoglobin
concentr
whole
blood
normal
one
third
hct
ie
mchc
red
cell
approxim
hemoglobin
mean
cell
volum
mcv
express
femtolit
fl
liter
indic
volum
averag
red
cell
sampl
mean
cell
hemoglobin
mch
repres
absolut
amount
hemoglobin
averag
red
cell
sampl
unit
picogram
pg
per
cell
mch
calcul
hb
rbc
valu
use
follow
equat
mchc
mean
cell
hemoglobin
concentr
express
gdl
calcul
hb
pcv
use
mchc
hb
pcv
term
hypochrom
use
red
cell
popul
valu
refer
interv
occur
strongli
regen
anemia
increas
popul
reticulocyt
low
hb
content
pull
averag
valu
low
mchc
also
occur
iron
defici
anemia
microcyt
hypochrom
red
cell
produc
lack
iron
support
hemoglobin
synthesi
reticulocyt
releas
increas
number
blood
bone
marrow
respons
anemia
young
anucl
erythrocyt
hemolysi
destruct
loss
hemorrhag
erythrocyt
speci
caus
anemia
determin
whether
bone
marrow
respond
anemia
given
suffici
time
increas
red
blood
cell
product
identif
immatur
anucl
red
blood
cell
requir
term
regen
respons
detect
immatur
erythrocyt
virtu
presenc
rna
form
ribosom
rough
endoplasm
reticulum
cytoplasm
requir
evalu
bone
marrow
respons
immatur
cell
rna
contain
contrast
matur
red
blood
cell
longer
synthes
hemoglobin
contain
small
amount
rna
b
white
blood
cell
basophil
eosinophil
lymphocyt
macrophagemonocyt
neutrophil
leukocyt
larg
unstain
cell
wbc
thousandsml
total
number
leukocyt
count
nuclei
total
nucleat
cell
count
nucleat
red
blood
cell
nrbc
circul
blood
includ
nucleat
cell
count
wbc
case
repres
leukocyt
count
correct
nucleat
red
cell
nrbc
correct
made
follow
c
clot
paramet
mean
platelet
volum
fibrinogen
prothrombin
time
activ
partialthromboplastin
time
platelet
play
fundament
role
hemostasi
format
blood
clot
natur
sourc
growth
factor
subject
estim
platelet
number
could
made
examin
stain
blood
film
plate
smear
size
number
platelet
clump
includ
toxicolog
studi
vaccin
adjuv
estim
fibrinogen
factor
synthes
liver
solubl
plasma
glycoprotein
convert
thrombin
fibrin
blood
coagul
form
clot
fibrin
cross
link
factor
xiii
shown
recent
research
fibrin
play
key
role
inflammatori
respons
develop
rheumatoid
arthriti
prothrombin
time
pt
blood
test
measur
time
take
plasma
clot
check
bleed
problem
check
whether
medicin
prevent
blood
clot
work
activ
partialthromboplastin
time
use
detect
abnorm
blood
clot
monitor
effect
heparin
treatment
urinalysi
urinalysi
physic
chemic
microscop
examin
urin
involv
number
test
detect
measur
variou
compound
pass
urin
array
test
perform
urin
one
common
method
medic
diagnosi
urin
sampl
test
follow
physic
color
appear
urin
look
like
nake
eye
clear
cloudi
b
pale
dark
yellow
anoth
color
c
urin
specif
graviti
test
reveal
concentr
dilut
urin
microscop
appear
urin
sampl
examin
microscop
look
cell
urin
crystal
mucu
substanc
sampl
identifi
bacteria
germ
might
present
e
chemistri
special
stick
dipstick
test
variou
substanc
urin
stick
contain
littl
pad
chemic
chang
color
come
contact
substanc
interest
bone
marrow
smear
bone
marrow
sampl
usual
collect
posterior
iliac
crest
reason
bone
marrow
biopsi
includ
anemia
unknown
caus
leukopenia
leukocytosi
immatur
granulocyt
andor
blast
blood
occurr
unusu
cell
blood
dwarf
megakaryocyt
thrombocytopenia
mark
thrombocytosi
creactiv
protein
creactiv
protein
crp
primari
acut
phase
reactant
rabbit
monkey
human
speci
assay
crp
measur
commerci
avail
adequ
sampl
crp
indic
system
inflammatori
respons
could
indic
potenti
toxic
particularli
true
evid
toxic
weight
loss
also
found
acut
phase
reactant
nonspecif
inflammatori
respons
specif
associ
particular
type
varieti
class
injuri
eg
liver
renal
harm
crp
measur
rabbit
monkey
need
run
serum
electrophoresi
analysi
adequ
inform
acut
phase
reaction
gener
crp
data
crp
primari
acut
phase
reactant
rodent
rat
mous
howev
glycoprotein
respons
inflammatori
marker
henc
although
need
measur
crp
rodent
propos
use
studi
equival
respons
acut
phase
reactant
measur
altern
rodent
acut
phase
reactant
may
measur
plasma
electrophoresi
sinc
occur
fraction
part
differ
globulin
creatin
kinas
also
known
creatin
phosphokinas
cpk
phosphocreatin
kinas
enzym
express
variou
tissu
cell
type
inflammatori
respons
intramuscular
inject
vaccin
might
caus
minim
muscl
degener
may
reflect
creatin
kinas
level
inflammatori
respons
consid
part
expect
mechan
toxic
due
mean
vaccin
administr
clinic
creatin
kinas
assay
blood
test
marker
myocardi
infarct
heart
attack
rhabdomyolysi
sever
muscl
breakdown
muscular
dystrophi
autoimmun
myositid
acut
renal
failur
antibodi
analysi
serolog
critic
measur
immun
respons
vaccin
andor
adjuv
recommend
guidelin
homeostat
condit
bodi
maintain
protect
infecti
diseas
call
immun
immun
allow
individu
distinguish
foreign
materi
self
neutral
andor
elimin
foreign
matter
seri
delic
balanc
complex
multicellular
physiolog
mechan
promot
cellular
andor
humor
immun
respons
primari
purpos
vaccin
develop
serolog
data
help
demonstr
exposur
vaccin
confirm
relev
anim
model
evalu
potenti
toxic
vaccin
might
allow
correl
toxic
effect
immun
respons
induc
elisa
method
use
measur
specif
antibodi
respons
humor
arm
immun
respons
meantim
assay
measur
cytokinesecret
antigenspecif
tlymphocyt
ginterferon
elispot
use
evalu
cellular
arm
immun
respons
necropsi
anim
normal
euthan
differ
time
point
depend
studi
design
expect
respons
test
articl
investig
termin
anim
usual
necropsi
day
eg
day
last
treatment
help
investig
earli
effect
vaccin
recoveri
anim
normal
use
detect
delay
toxic
andor
determin
whether
preclin
toxicolog
vaccin
earlier
detect
effect
resolv
time
normal
number
anim
termin
recoveri
group
per
sex
histopatholog
evalu
gross
examin
conduct
major
organ
microscop
evalu
conduct
complet
list
tissu
site
vaccin
inject
quadricep
skin
quadricep
intramuscular
im
inject
examin
care
brain
kidney
liver
reproduct
organ
consid
pivot
evalu
advers
chang
immun
organ
spleen
thymu
drain
lymph
node
evalu
chang
might
indic
posit
andor
neg
respons
serious
histopatholog
find
case
depend
find
eg
clinic
patholog
result
exampl
vacuol
liver
normal
find
may
indic
toxic
vacuol
accompani
increas
clinic
chemistri
paramet
liver
enzym
would
concern
consid
indic
toxic
howev
vacuol
consid
adapt
respons
occur
without
accompani
chang
e
instanc
metabol
activ
could
lead
vacuol
mani
cell
type
would
accompani
chang
indic
frank
toxic
unless
sever
intend
immunolog
inflammatori
respons
vaccin
consid
advers
effect
repeat
dose
studi
inflamm
site
inject
hyperplasia
hypertrophi
lymph
node
drain
inject
site
increas
spleen
weight
clinic
patholog
chang
eg
increas
white
blood
cell
increas
serum
globulin
decreas
serum
albumin
consid
intend
immunolog
inflammatori
respons
reproduct
development
toxicolog
studi
includ
ind
packag
vaccin
studi
intend
administ
women
childbear
potenti
also
case
vaccin
specif
design
matern
immun
prevent
infecti
diseas
neonat
passiv
transfer
antibodi
eg
vaccin
group
b
streptococcu
life
threaten
neonat
period
except
certain
vaccin
may
automat
contraind
pregnant
women
plan
becom
pregnant
e
exampl
smallpox
vaccin
contraind
women
pregnant
women
plan
becom
pregnant
within
week
vaccin
addit
pregnant
women
advis
avoid
close
contact
person
recent
vaccin
case
rubella
studi
potenti
effect
vaccin
fertil
fetal
develop
postnat
develop
offspr
critic
sexual
organ
function
endocrin
regul
fertil
transport
fertil
ovum
implant
develop
could
affect
toxic
effect
vaccin
abnorm
develop
fertil
egg
embryo
fetu
offspr
way
matur
due
test
vaccin
exposur
subset
reproduct
toxicolog
call
development
toxicolog
development
studi
includ
studi
prenat
embryon
fetal
postnat
develop
follow
birth
enddifferenti
organ
achiev
event
choic
speci
depend
vaccin
immunogen
rel
rate
time
placent
transfer
antibodi
exampl
rat
mice
antibodi
transfer
postnat
milk
howev
major
antibodi
transfer
rabbit
occur
across
placenta
prenat
reproduct
studi
design
follow
ich
guidelin
one
speci
requir
kind
studi
anim
immun
week
mate
boost
immedi
prior
mate
figur
one
subset
pregnant
femal
submit
cesarean
section
fetal
examin
gestat
day
gd
mice
gd
rat
anoth
subset
group
allow
litter
postnat
develop
pnd
pup
follow
wean
rodent
e
pnd
assess
potenti
longlast
perman
chang
studi
could
extend
includ
assess
immun
system
development
immunotox
test
offspr
week
serum
antibodi
level
determin
follow
femal
predos
end
gestat
lactat
period
fetu
cord
blood
pup
postnat
day
addit
assess
conduct
histochem
analysi
antibodi
deposit
could
conduct
vaccin
induc
advers
effect
neurolog
assess
immunolog
endpoint
could
also
includ
cber
guidelin
indic
subject
may
includ
clinic
trial
without
development
toxic
studi
provid
appropri
precaut
taken
avoid
vaccin
pregnanc
development
toxic
studi
report
suppli
biolog
licens
applic
bla
submiss
depend
avail
toxicolog
inform
preclin
clinic
studi
test
articl
assign
differ
pregnanc
categori
fda
assign
follow
pregnanc
categori
adequ
wellcontrol
studi
fail
demonstr
risk
fetu
first
trimest
pregnanc
evid
risk
later
trimest
women
anim
reproduct
studi
fail
demonstr
risk
fetu
adequ
wellcontrol
studi
pregnant
women
anim
reproduct
studi
shown
advers
effect
fetu
adequ
wellcontrol
studi
human
potenti
benefit
may
warrant
use
drug
pregnant
women
despit
potenti
risk
posit
evid
human
fetal
risk
base
advers
reaction
data
investig
market
experi
studi
human
potenti
benefit
may
warrant
use
drug
pregnant
women
despit
potenti
risk
studi
anim
human
demonstr
fetal
abnorm
andor
posit
evid
human
fetal
risk
base
advers
reaction
data
investig
market
experi
risk
involv
use
drug
pregnant
women
clearli
outweigh
potenti
benefit
gener
mutagen
studi
requir
vaccin
guidelin
nonclin
evalu
vaccin
european
medicin
evalu
agenc
emea
genotox
studi
might
relev
adjuv
biolog
origin
potenti
gene
mutat
chromosom
aberr
primari
dna
damag
might
need
synthet
adjuv
consid
new
chemic
entiti
gener
carcinogen
studi
requir
vaccin
guidelin
nonclin
evalu
vaccin
emea
low
dose
low
usag
adjuv
mean
risk
tumor
induct
small
accord
emea
guidelin
studi
perform
evalu
advers
effect
test
articl
physiolog
function
cardiovascular
system
respiratori
system
central
nervou
system
central
nervou
system
studi
includ
evalu
motor
activ
behavior
chang
coordin
sensori
motor
reflex
respons
bodi
temperatur
cardiovascular
system
evalu
includ
blood
pressur
heart
rate
electrocardiogram
measur
vivo
vitro
andor
ex
vivo
evalu
includ
method
repolar
conduct
abnorm
also
consid
respiratori
rate
tidal
volum
hemoglobin
oxygen
satur
measur
part
respiratori
system
evalu
vaccin
separ
safeti
pharmacolog
studi
perform
studi
evalu
bodi
temperatur
electrocardiogram
central
nervou
system
could
includ
repeatdos
toxic
studi
need
detail
safeti
pharmacolog
studi
reader
refer
guidanc
industri
safeti
pharmacolog
studi
human
pharmaceut
certain
type
vaccin
special
toxic
studi
need
new
live
attenu
viru
vaccin
either
theoret
establish
potenti
revers
attenu
neurotrop
activ
virul
neurovirul
studi
need
polio
yellow
fever
vaccin
fall
categori
base
detail
knowledg
neurotrop
behavior
neurovirul
test
nvt
polio
vaccin
part
routin
batch
releas
procedur
yellow
fever
vaccin
design
allow
quantit
assess
effect
viru
examin
specif
area
follow
direct
inocul
vaccin
good
safeti
record
measl
mump
varicella
virus
requir
reevalu
neurovirul
test
minim
chang
seed
lot
manufactur
sinc
earli
new
approach
vaccin
activ
develop
includ
direct
introduct
plasmid
dna
contain
gene
encod
antigen
immun
respons
sought
incorpor
antigen
appropri
host
tissu
situ
product
target
antigen
advantag
approach
tradit
approach
stimul
band
tcell
respons
vaccin
improv
stabil
absenc
infecti
agent
rel
eas
larg
scale
manufactur
vaccin
gener
use
biolog
medicin
product
prophylaxi
infecti
diseas
dna
vaccin
also
develop
therapeut
use
eg
infecti
diseas
diseas
cancer
use
gene
varieti
infecti
agent
includ
influenza
viru
hepat
b
viru
human
immunodefici
viru
rabi
viru
lymphocyt
choriomening
viru
west
nile
viru
malaria
mycoplasma
mani
scientif
public
explor
potenti
dna
vaccin
immun
respons
anim
nucleic
acid
viral
vectorbas
vaccin
biodistribut
studi
necessari
determin
tissu
distribut
follow
administr
potenti
vector
integr
host
genom
design
nonclin
safeti
test
take
consider
use
dna
vaccin
riskbenefit
situat
addit
follow
glp
requir
preclin
toxicolog
studi
see
dna
studi
also
evalu
local
inflammatori
respons
eg
myositi
organ
specif
autoimmun
immunopatholog
relev
paramet
particular
encod
antigen
selfantigen
may
show
selfantigen
mimicri
wider
rang
studi
includ
autoantibodi
may
necessari
address
specif
concern
pasteur
investig
anthrax
pasteurella
multocida
rabi
pathogenesi
anim
model
confirm
differ
speci
could
infect
certain
pathogen
also
confirm
old
cultur
p
multocida
chicken
cholera
kept
laboratori
without
passag
could
protect
chicken
virul
p
multocida
challeng
concept
vaccin
dog
rabi
also
discov
pasteur
exampl
anim
usag
vaccin
research
includ
use
viruslik
particl
vlp
immun
papillomaviru
control
diseas
caus
bovin
canin
rabbit
papillomaviru
recombin
papillomaviru
vlp
use
provid
basi
subsequ
licensur
bival
quadraval
hpv
vaccin
prevent
cervic
cancer
confirm
develop
vaccin
studi
anim
remain
relev
control
infecti
diseas
human
anim
model
human
vaccin
develop
differ
applic
whether
studi
intend
studi
toxicolog
measur
efficaci
new
vaccin
select
right
anim
model
critic
instanc
limit
number
host
includ
nonhuman
primat
germfre
barrier
rais
piglet
germfre
dog
cat
colon
helicobact
pylori
investig
prefer
work
small
anim
larger
anim
exampl
ferret
success
use
investig
gastriti
antimicrobi
agent
h
feli
mice
use
anim
model
studi
h
pylori
abil
reproduc
aspect
relev
human
physiolog
hallmark
appropri
anim
model
util
vaccin
develop
human
anim
ultim
target
popul
vaccin
good
model
share
physiolog
characterist
ie
human
pig
share
physiolog
skin
least
reflect
close
possibl
ethic
use
anim
human
vaccin
research
requir
select
match
human
diseas
close
possibl
overal
number
anim
use
biomed
research
reduc
accord
criterion
anatom
physiolog
immun
system
differ
speci
influenc
rel
respons
part
effort
find
develop
new
vaccin
adjuv
anim
model
typic
use
discrimin
variou
antigen
combin
differ
adjuv
anim
model
use
possess
biolog
complex
immun
system
may
predict
human
potenti
advers
effect
although
model
transgen
anim
exist
possess
enhanc
qualiti
repres
variou
aspect
pertin
model
human
immun
system
commonli
use
toxic
assess
time
strain
antigen
depend
immunolog
respons
occur
rat
mice
differ
exist
humor
cell
mediat
immun
host
criteria
consid
choos
anim
model
vaccin
develop
similar
elucid
aspect
immun
physiolog
vivo
mous
excel
anim
model
although
frequent
use
limit
studi
etiolog
infect
diseas
pathogenesi
murin
model
suitabl
studi
acut
extracellular
bacteri
infect
limit
valu
studi
intracellular
viral
bacteri
parasit
infect
valu
mice
rat
model
studi
intracellular
infect
limit
complex
uniqu
etiolog
intracellular
infect
narrow
host
rang
infect
individu
pathogen
except
gener
concept
small
number
specif
intracellular
murin
infect
like
one
involv
lymphocyt
choriomeningit
viru
infect
yield
uniqu
insight
understand
protect
immun
intracellular
infect
primat
guinea
pig
rabbit
cat
ferret
use
select
relev
model
studi
vaccin
earlier
studi
tuberculosi
tb
recent
simian
immunodefici
viru
siv
studi
model
tb
hiv
human
primat
model
use
experiment
infect
model
evalu
human
tuberculosi
vaccin
guinea
pig
use
guinea
pig
inordin
suscept
tuberculosi
follow
infect
mycobacterium
tuberculosi
bovi
potenti
use
studi
pathogenesi
may
limit
valu
guinea
pig
model
studi
tb
protect
immun
produc
tubercl
granulomat
diseas
similar
found
domest
livestock
human
guinea
pig
use
extens
tuberculosi
research
orm
im
et
al
report
advantag
disadvantag
rang
anim
model
tuberculosi
shown
tabl
human
influenza
viru
isol
replic
upper
lower
respiratori
tract
clinic
sign
diseas
reason
viru
dose
ferret
use
studi
support
safeti
live
influenza
vaccin
howev
antigenspecif
tcell
easili
measur
lymph
node
circul
lung
mous
anim
model
suitabl
gener
data
support
potenti
immunogen
novel
vaccin
target
induct
effector
cell
understand
mechan
immun
protect
contribut
iga
igg
cd
cd
tcell
immun
mice
use
regular
basi
mice
use
evalu
pathogenesi
avian
influenza
virus
viru
examin
protect
activ
vaccin
strain
anim
model
abovement
advantag
use
mice
influenza
studi
offset
disadvantag
one
mice
natur
host
influenza
viru
thu
determin
vaccin
effect
studi
usual
perform
viru
strain
adapt
replic
mice
altern
larg
inocula
administ
directli
lower
respiratori
tract
induc
diseas
prior
use
model
test
novel
vaccin
differ
mous
human
innat
adapt
immunolog
interact
consid
rsv
infect
balbc
mous
use
mimic
human
respiratori
diseas
cotton
rat
also
use
studi
immun
viral
pathogenesi
clinic
sign
infect
evid
intranas
inocul
reason
viru
dose
model
addit
model
respiratori
rate
measur
influenza
virusinduc
diseas
help
provid
relev
endpoint
evalu
diseas
live
anim
extend
period
time
cotton
rat
also
good
model
evalu
impact
earli
innat
respons
immun
mice
cotton
rat
good
model
evalu
spread
infect
anim
influenza
virus
transmiss
guinea
pig
good
model
use
studi
anim
model
support
influenza
viru
replic
upper
lower
respiratori
tract
addit
guinea
pig
provid
mean
compar
effect
influenza
vaccin
show
differ
protect
immun
inactiv
live
attenu
vaccin
howev
correl
endpoint
anim
model
infect
diseas
rate
human
demonstr
real
valu
determin
impact
vaccin
viru
transmiss
guinea
pig
question
ferret
use
influenza
viru
studi
sinc
experi
anim
show
sign
diseas
follow
inocul
filter
nasal
secret
individu
respiratori
symptom
human
highli
pathogen
ferret
induc
sneez
cough
fever
weight
loss
diarrhea
neurolog
sign
could
viru
replic
nasal
turbin
lung
spread
brain
spleen
intestin
anim
therefor
ferret
commonli
use
evalu
immunogen
effect
pandem
influenza
vaccin
advantag
disadvantag
anim
model
studi
influenza
viru
eichelberg
green
consult
renew
interest
pig
model
studi
influenza
virus
emerg
pandem
swineorigin
strain
nasal
discharg
cough
fever
labor
breath
weight
loss
report
pig
caus
certain
swine
strain
made
anim
use
model
studi
immun
pathogenesi
studi
pandem
viru
specificpathogenfre
spf
miniatur
pig
use
model
particularli
attract
avail
number
reagent
enabl
studi
immun
correl
protect
highli
pathogen
avian
virus
caus
sever
clinic
sign
diseas
pig
howev
highli
pathogen
virus
caus
diseas
death
cat
thu
cat
consid
good
model
test
protect
diseas
death
due
highli
pathogen
avianorigin
strain
viru
caus
moder
level
diseas
cat
infect
intratrach
replic
primarili
lung
also
isol
organ
pig
cat
extens
use
studi
pathogenesi
immun
transmiss
human
influenza
therefor
current
use
routin
support
human
vaccin
studi
cynomolgu
rhesu
pigtail
macaqu
use
influenza
viru
infect
cynomolgu
macaqu
design
good
model
studi
viru
type
monkey
show
atyp
innat
immun
respons
correl
lethal
diseas
also
use
evalu
effect
recombin
modifi
vaccinia
ankara
viru
express
ha
highli
pathogen
infect
gener
studi
influenza
distemp
infect
ferret
use
immunolog
cell
transfer
histoincompat
outbr
individu
use
outbr
anim
limit
cat
use
studi
felin
immunodefici
viru
fiv
analog
hiv
infect
human
wherea
rabbit
use
studi
immun
varieti
toxinogen
bacteri
infect
requir
neutral
antibodi
main
pathway
protect
guinea
pig
first
model
use
leishmania
enrietti
infect
tcell
respons
parasit
antigen
develop
within
two
week
infect
lesion
heal
week
guinea
pig
infect
inbr
mice
leishmania
speci
pathogen
human
supersed
l
enriettii
guinea
pig
model
spectrum
diseas
manifest
observ
human
leishmaniasi
mimick
laboratori
infect
differ
inbr
strain
mice
l
major
includ
rang
suscept
state
depend
strain
mous
use
mous
model
reproduc
mani
aspect
human
diseas
upon
infect
balbc
mice
develop
larg
skin
ulcer
expand
metastas
lead
death
howev
cban
mice
resist
develop
small
lesion
cure
week
resist
reinfect
intermedi
suscept
report
strain
mice
suscept
resist
mice
produc
cytokin
period
activ
lesion
develop
differ
suscept
resist
mice
latter
abl
switch
profil
control
diseas
golden
hamster
one
earli
anim
model
studi
viscer
leishmaniasi
viscer
diseas
death
result
infect
l
donovani
model
aspect
human
diseas
mimick
hamster
anemia
hyperglobulinemia
cachexia
make
use
tool
character
molecul
mechan
involv
pathogenesi
recent
hamster
use
primarili
sourc
l
donovani
amastigot
seem
requir
life
cycl
stage
infect
mice
current
prefer
model
anim
viscer
leishmaniasi
inbr
strain
mice
display
mark
differ
suscept
infect
l
donovani
best
anim
model
viscer
leishmaniasi
dog
relev
immunolog
studi
vaccin
develop
perform
human
speci
suscept
infect
great
ape
chimpanze
use
studi
viru
limit
includ
scarciti
anim
cost
limit
viral
replic
absenc
diseas
infect
patient
isol
asian
macaqu
monkey
use
good
model
simian
innumodefici
viru
siv
studi
sivinfect
macaqu
use
model
assess
vaccin
strategi
develop
aidslik
diseas
limit
includ
differ
viral
sequenc
envelop
epitop
recent
chimer
virus
construct
laboratori
express
envelop
siv
backbon
construct
virus
call
simianhuman
immunodefici
virus
shiv
macaqu
vivo
passag
chimer
virus
result
shiv
induct
lymphocyt
loss
death
result
opportunist
infect
genit
diseas
guinea
pig
close
resembl
human
use
test
potenti
vaccin
antivir
chemotherapi
genit
herp
mcclement
et
al
report
immun
dna
encod
herp
simplex
viru
type
full
length
glycoprotein
gd
truncat
form
gb
induc
immun
respons
mice
protect
lethal
challeng
also
show
combin
two
dna
protect
guinea
pig
primari
genit
diseas
mcclement
et
al
also
found
protect
immun
could
induc
low
dose
dna
mous
model
singl
immun
also
shown
investig
protect
immun
mous
guinea
pig
hsvinfect
model
induc
multipl
immun
higher
dose
gd
dna
gb
dna
provost
et
al
report
marmoset
chimpanze
use
model
hepat
viru
hav
behavior
man
select
right
anim
model
vaccin
develop
safeti
efficaci
taken
equal
consider
safe
vaccin
without
good
efficaci
use
vice
versa
good
understand
respons
vaccin
neonat
elderli
also
requir
increas
risk
contract
infecti
diseas
studi
mous
model
suggest
vaccin
respons
may
compromis
age
group
develop
murin
immun
system
may
provid
appropri
model
evalu
immun
respons
two
age
group
evalu
vaccin
immun
respons
neonat
address
question
regard
possibl
interact
vaccin
matern
antibodi
larg
anim
model
may
much
appropri
howev
mice
investig
vaccin
respons
geriatr
anim
screen
adjuv
hors
could
provid
geriatr
popul
appropri
anim
model
also
need
develop
mucos
vaccin
diseas
protect
wide
varieti
pathogen
invad
mucos
surfac
could
achiev
mucos
vaccin
difficulti
associ
effici
vaccin
deliveri
weak
immun
respons
follow
mucos
immun
made
induct
protect
immun
respons
mucos
surfac
elus
goal
thu
evalu
mucos
vaccin
deliveri
technolog
effect
safe
mucos
adjuv
character
mucos
immun
respons
appropri
anim
model
requir
mice
intranas
vaccin
may
associ
inhal
ingest
vaccin
antigen
make
difficult
discrimin
intranas
oral
intrapulmonari
vaccin
howev
larger
anim
like
pig
cow
use
control
deliveri
vaccin
nasal
passag
nasal
passag
anim
close
resembl
human
mous
surgic
model
also
use
screen
varieti
mucos
vaccin
deliveri
technolog
potenti
mucos
adjuv
critic
choos
anim
model
ensur
select
model
simul
close
possibl
event
occur
human
greater
similar
pattern
pathogenesi
two
like
relev
correl
immunemedi
protect
eman
model
rout
exposur
use
respiratori
tract
pathogen
rout
entranc
aerosol
challeng
expos
pathogen
defens
upper
respiratori
tract
use
intratrach
challeng
would
consid
appropri
circumv
variou
barrier
upper
respiratori
tract
similar
pathogen
dose
would
occur
natur
use
use
excess
pathogen
challeng
unnatur
rout
infect
might
overcom
adapt
immun
respons
structur
function
develop
respiratori
tract
anim
model
resembl
human
choos
model
respiratori
infect
abovement
reason
anim
model
continu
play
critic
role
human
vaccin
develop
especi
preclin
discoveri
phase
thu
critic
choos
appropri
model
restrict
investig
least
expens
conveni
anim
model
help
make
optim
use
anim
rapidli
bring
safe
effect
vaccin
market
select
appropri
rout
vaccin
administr
critic
compon
success
immun
vaccin
normal
administ
inject
either
intraven
iv
intramuscular
im
subcutan
sc
administr
advantag
disadvantag
rout
administr
vaccin
could
also
administ
oral
intranas
rout
also
advantag
disadvantag
discuss
later
section
intramuscular
im
vaccin
administr
needl
use
administ
vaccin
muscl
long
enough
reach
deep
muscl
insert
angl
skin
quick
thrust
necessari
aspir
use
rout
minimum
inch
separ
necessari
use
multipl
inject
extrem
follow
vaccin
administ
intramuscular
im
rout
diphtheriatetanu
dt
td
pertussi
dtap
tdap
hemophilu
influenza
type
b
hib
hepat
hepa
hepat
b
hepb
human
papillomaviru
hpv
inactiv
influenza
tiv
quadrival
meningococc
conjug
pneumococc
conjug
pcv
inactiv
polio
ipv
pneumococc
polysaccharid
could
administ
either
im
sc
rout
subcutan
sc
vaccin
administr
subcutan
tissu
pinch
prevent
inject
muscl
needl
insert
angl
skin
necessari
aspir
use
rout
minimum
inch
separ
necessari
use
multipl
inject
extrem
follow
vaccin
administ
sc
rout
measl
mump
rubella
mmr
varicella
var
meningococc
polysaccharid
zoster
shingl
zo
optim
immunogen
vaccin
minim
advers
reaction
inject
site
vaccin
given
via
intramuscular
rout
deltoid
anterolater
aspect
thigh
vaccin
failur
might
result
inject
vaccin
layer
subcutan
fat
poor
vascular
might
result
slow
mobil
process
antigen
might
case
hepat
b
rabi
influenza
vaccin
subcutan
inject
hepat
b
vaccin
lead
signific
lower
seroconvers
rate
rapid
decay
antibodi
respons
compar
intramuscular
administr
initi
immun
respons
appropri
cell
eg
phagocyt
antigenpres
cell
involv
layer
fat
contain
cell
deposit
fat
antigen
may
take
longer
reach
circul
potenti
lead
delay
process
macrophag
eventu
present
tand
bcell
immun
respons
antigen
may
also
denatur
enzym
remain
fat
hour
day
thicker
skin
fold
associ
lower
antibodi
respons
vaccin
adipos
tissu
much
poorer
drainag
channel
muscl
retain
inject
materi
longer
period
therefor
suscept
advers
effect
thu
subcutan
inject
caus
abscess
granuloma
abund
blood
suppli
muscl
tissu
probabl
spare
harm
effect
substanc
inject
antigen
adsorb
aluminum
salt
adjuv
hepat
hepat
b
diphtheria
tetanu
pertussi
vaccin
henc
intramuscular
rout
strongli
prefer
superfici
administr
vaccin
may
lead
increas
incid
local
reaction
irrit
inflamm
granuloma
format
necrosi
deep
substanc
inject
determin
inject
techniqu
needl
size
wide
variat
exist
thick
deltoid
fat
pad
women
significantli
subcutan
fat
men
use
longer
needl
might
caus
patient
discomfort
skelet
muscl
poorer
suppli
pain
fiber
skin
subcutan
tissu
discomfort
might
less
needl
gaug
anoth
import
factor
vaccin
administr
vaccin
dissip
wider
area
use
wider
bore
needl
reduc
risk
local
red
swell
altern
rout
administr
use
improv
protect
immun
respons
place
bodi
certain
virus
bacteria
like
target
intranas
vaccin
induc
protect
immun
respiratori
tract
virus
attack
either
slow
rate
uptak
antigen
eg
intranas
vaccin
taken
bodi
slowli
inject
vaccin
thu
reduc
risk
allerg
reaction
administ
vaccin
virus
area
bodi
typic
grow
thu
reduc
diseasecaus
effect
strain
live
vaccin
virus
sideeffect
vaccin
reduc
intranas
administr
easi
accept
human
anim
avirul
intranas
vaccin
could
given
via
nostril
use
special
applic
cell
line
upper
respiratori
tract
nasal
passag
throat
trachea
would
coat
vaccin
viru
would
subsequ
replic
cell
virus
andor
bacteria
attack
immun
cell
present
respiratori
tract
induc
protect
immun
respons
tend
remain
within
near
respiratori
tract
anim
receiv
intranas
vaccin
line
respiratori
tract
would
coat
protect
antibodi
hundr
memori
cell
prime
recogn
antigen
contain
invad
respiratori
virus
includ
region
respiratorysystem
lymph
node
invad
virus
bacteria
reach
respiratori
tract
antibodi
memori
cell
would
react
elimin
respons
much
rapid
produc
inject
vaccin
result
immun
defens
locat
region
invad
pathogen
invad
virus
get
opportun
damag
mani
cell
case
moreov
clinic
sign
diseas
occur
mild
advantag
disadvantag
intranas
vaccin
advantag
improv
patient
complianc
improv
penetr
lipophil
low
molecular
weight
drug
nasal
mucosa
due
larg
absorpt
surfac
high
vascular
rapid
absorpt
fast
onset
action
expect
avoid
gastrointestin
tract
environment
condit
chemic
enzymat
degrad
drug
hepat
first
pass
metabol
direct
deliveri
vaccin
lymphat
tissu
induct
secretori
immun
respons
distant
mucos
site
uptak
viral
antigen
bodi
slower
intranas
vaccin
allerg
reaction
less
like
happen
disadvantag
mild
upper
respiratori
tract
infect
could
induc
character
wateri
nasal
ocular
discharg
sneez
even
cough
howev
usual
self
limit
mild
gener
effect
respiratori
pathogen
intranas
vaccin
need
everi
year
sever
liver
damag
even
death
anim
could
caus
accident
inject
intranas
bordetella
vaccin
penetr
brain
olfactori
region
may
caus
nasal
administ
substanc
includ
toxin
attenu
microorgan
vaccin
drug
target
neurolog
diseas
direct
nosetobrain
transport
may
advantag
rais
concern
potenti
advers
effect
brain
target
organ
noninject
rout
exist
besid
intranas
applic
orallyand
intraperitoneallyadminist
vaccin
given
abdomin
caviti
investig
approv
human
use
rout
use
improv
respons
gastrointestin
immun
system
diseas
like
parvoviru
coronaviru
polio
vaccin
rotaviru
adeno
typhoid
exampl
oral
administ
vaccin
dermal
patch
spray
vaccin
appli
skin
surfac
transderm
vaccin
aerosol
vaccin
particl
forc
high
pressur
skin
use
special
instrument
thu
avoid
need
needl
develop
dna
plasmid
vaccin
typic
administ
im
id
rout
may
given
electropor
propel
dnacoat
gold
particl
variou
tissu
kill
subunit
vaccin
replic
stay
one
spot
immun
system
kill
without
viru
replic
immun
system
becom
expos
massiv
amount
antigen
gener
live
virus
ineffici
humor
immun
fewer
memori
bcell
smaller
amount
antibodi
nt
last
bodi
long
cell
mediat
immun
mani
memori
tcell
wait
target
next
wildtyp
viru
come
along
develop
humor
cellmedi
immun
improv
ad
larg
quantiti
kill
viru
bacteri
matter
inactiv
vaccin
amount
antigen
avail
immun
system
recogn
increas
way
howev
increas
risk
allerg
local
inflammatori
inject
site
reaction
ad
adjuv
vaccin
design
increas
effect
immun
respons
howev
adjuv
might
increas
risk
allerg
reaction
anaphylaxi
inject
site
reaction
requir
minimum
two
dose
achiev
desir
effect
risk
vaccin
reaction
second
dose
must
given
inject
avail
rout
administr
live
vaccin
amplifi
promot
longer
last
humor
cellmedi
immun
respons
result
longer
last
rapidli
induc
immun
protect
replic
bodi
small
amount
viral
materi
need
inject
less
viral
materi
mean
reduc
risk
allerg
inject
site
reaction
adjuv
requir
kind
vaccin
henc
risk
allerg
inject
site
reaction
reduc
inject
live
vaccin
given
rout
eg
intranas
thu
live
vaccin
potenti
tailor
induc
immun
area
bodi
effect
eg
immun
respiratori
system
protect
respiratori
virus
drawback
live
vaccin
must
store
care
potenc
may
lost
immunocompromis
pregnant
animalshuman
might
get
diseas
sever
complic
might
caus
certain
live
vaccin
eg
live
rabi
vaccin
caus
fatal
neurolog
diseas
dog
cat
poorli
produc
vaccin
may
contain
virul
organ
could
produc
sever
diseas
live
vaccin
caus
sever
ill
given
wrong
rout
eg
inject
cat
flu
vaccin
virus
accident
get
inhal
cat
produc
mark
sign
catflu
intranas
bordetella
vaccin
virus
caus
liver
damag
death
inject
addit
toxic
studi
vivo
vitro
assay
play
signific
role
assess
critic
safeti
characterist
vaccin
test
encompass
assess
ident
puriti
safeti
efficaci
term
antigen
potenc
gener
type
studi
aim
detect
undesir
contamin
impur
character
vaccin
product
ensur
conform
specifi
manufactur
standard
unlik
toxic
studi
explor
potenti
unanticip
risk
refin
understand
advers
effect
product
character
studi
emphas
quantifi
examin
aspect
associ
properti
vaccin
potenc
import
consist
safe
manufactur
vaccin
respect
studi
may
consid
focus
toxic
studi
restrict
narrow
endpoint
includ
surviv
clinic
sign
among
import
test
potenc
gener
safeti
neurovirul
iab
scientif
workshop
neurovirul
test
live
vaccin
tumorigen
meet
report
studi
group
cell
substrat
product
biolog
european
pharmacopoeia
section
pyrogen
degre
natur
test
depend
immunolog
mechan
involv
action
vaccin
natur
potenti
unwant
constitu
vaccin
potenc
test
typic
measur
level
protect
either
direct
challeng
use
known
quantiti
infecti
organ
indirectli
exposur
serum
contain
neutral
antibodi
follow
incub
toxin
determin
potenc
gener
made
seri
dilut
compar
standard
refer
unlik
typic
immun
protocol
util
prime
boost
strategi
success
inject
space
time
immunogen
test
product
character
often
limit
singl
inject
initi
respons
believ
better
discrimin
amount
qualiti
immunogen
infrequ
seriou
toxic
associ
vaccin
often
link
manufactur
process
earli
lot
polio
salk
vaccin
complet
inactiv
allow
contamin
live
poliovirus
result
paralysi
individu
addit
contamin
commerci
vaccin
polioviru
adenoviru
yellow
fever
later
demonstr
potenti
harm
among
differ
type
product
character
studi
toxicityrel
endpoint
follow
insert
mutagenesi
dna
vaccin
attenu
untoward
immun
e
hypersensit
autoimmun
break
immun
toler
pediatr
evalu
requir
part
new
drug
biolog
licens
applic
us
everi
market
author
applic
europ
unless
waiver
grant
advis
acquir
approv
regulatori
agenc
fda
ema
pediatr
develop
plan
start
pediatr
clinic
trial
juvenil
toxic
studi
pharmacolog
activ
demonstr
one
speci
accept
rat
recommend
speci
relev
development
system
easili
monitor
anim
model
could
use
care
consider
organ
system
develop
rel
human
speci
select
limit
target
specif
nonhuman
primat
nhp
suitabl
speci
toxic
assess
core
requir
preclin
test
biopharmaceut
establish
pharmacolog
relev
test
speci
morford
et
al
report
advantag
disadvantag
speci
nhp
rodent
dog
minipig
juvenil
toxic
test
biopharmaceut
number
document
develop
variou
regulatori
agenc
provid
supplementari
inform
concern
variou
aspect
topic
discuss
chapter
